0000000000189998

AUTHOR

A. Mark Richards

showing 2 related works from this author

Rapid Rule-out of Acute Myocardial Infarction With a Single High-Sensitivity Cardiac Troponin T Measurement Below the Limit of Detection: A Collabora…

2017

Background: High-sensitivity assays for cardiac troponin T (hs-cTnT) are sometimes used to rapidly rule out acute myocardial infarction (AMI).Purpose: To estimate the ability of a single hs-cTnT concentration below the limit of detection (<0.005 µg/L) and a nonischemic electrocardiogram (ECG) to rule out AMI in adults presenting to the emergency department (ED) with chest pain.Data Sources: EMBASE and MEDLINE without language restrictions (1 January 2008 to 14 December 2016).Study Selection: Cohort studies involving adults presenting to the ED with possible acute coronary syndrome in whom an ECG and hs-cTnT measurements were obtained and AMI outcomes adjudicated during initial hospitaliz…

MaleChest Painmedicine.medical_specialtyAcute coronary syndromeMyocardial Infarction030204 cardiovascular system & hematologyChest pain03 medical and health sciencesHospitalElectrocardiography0302 clinical medicineTroponin TLimit of DetectionInternal medicineJournal ArticleInternal MedicinemedicineHumans030212 general & internal medicineMyocardial infarctioncardiovascular diseasesAgedTroponin T/bloodEmergency ServicebiologyTroponin Tbusiness.industryChest Pain/etiologyGeneral MedicineEmergency departmentMiddle Agedmedicine.diseaseTroponinbiology.proteinCardiologyFemalemedicine.symptombusinessEmergency Service HospitalMyocardial Infarction/bloodMaceMeta-AnalysisCohort study
researchProduct

The Peptide for Life Initiative: a call for action to provide equal access to the use of natriuretic peptides in the diagnosis of acute heart failure…

2021

n/a Funding Agencies|Applied Therapeutics; Innolife; Novartis PharmaceuticalsNovartis; Abbott DiagnosticsAbbott Laboratories; AstraZenecaAstraZeneca; AbbottAbbott Laboratories; Boehringer IngelheimBoehringer Ingelheim; Cardior Pharmaceuticals Gmbh; Ionis Pharmaceuticals, Inc.; Novo NordiskNovo Nordisk; RocheRoche Holding; Swiss National Science FoundationSwiss National Science Foundation (SNSF)European Commission; Swiss Heart Foundation; KTI; European UnionEuropean Commission; University of Basel; University Hospital Basel; Beckman Coulter; BRAHMS; Idorsia; NovartisNovartis; Ortho Clinical Diagnostics; Quidel; SiemensSiemens AG; Singulex; Sphingotec; CardioRenal

medicine.medical_specialtyNT-PROBNPMEDLINE030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicine[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemNatriuretic Peptide BrainmedicineMANAGEMENTHumansCardiac and Cardiovascular Systems030212 general & internal medicineNatriuretic PeptidesIntensive care medicineDYSPNEAHeart FailureKardiologibusiness.industryEmergency departmentASSOCIATIONmedicine.diseasePeptide FragmentsEMERGENCY-DEPARTMENT3. Good health[SDV.MHEP.CSC] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemEuropeAction (philosophy)Heart failurePeptidesCardiology and Cardiovascular MedicinebusinessAtrial Natriuretic FactorBiomarkers
researchProduct